R1 Rcm Inc Stock Price, News & Analysis

R1 RCM (NASDAQ: RCM) announced the release date for its financial results for Q1 2023, which will occur on May 4, 2023, before market opening. The results will be discussed in a conference call scheduled for 8:00 a.m. ET on the same day. Interested participants can join by calling 888-330-2022 (or 646-960-0690 outside the U.S. and Canada), using conference code 5681952. The conference call will also be available via a live webcast on the company's website.

R1 RCM provides technology-driven solutions aimed at enhancing the patient experience and financial performance of healthcare providers. The company's scalable operating models are designed to improve net patient revenue, cash flow, and reduce operating costs.

R1 RCM (NASDAQ: RCM) has released its 2022 Environmental, Social, and Governance (ESG) report, showcasing its commitment to sustainability and corporate responsibility. The report highlights R1's efforts in improving employee experiences for over 27,000 global staff, community support, and environmental initiatives. Notable achievements include recognition by the Human Rights Campaign for LGBTQ+ workplace inclusivity, over 19,500 volunteer hours to 1,700 organizations, and a substantial $500,000 donation to the Nurse-Family Partnership. R1 aims to plant 10,600 trees in India by 2026 to enhance air quality and tackle climate change.

R1 RCM, a leading provider of technology-driven solutions for healthcare providers, announced its participation in two significant conferences. The company will present at the 43rd Annual Cowen Health Care Conference on March 7, 2023, at 11:10 am ET, and at the Barclays Global Healthcare Conference on March 16, 2023, at 8:00 am ET. A live audio webcast of the presentations will be available on R1's Investor Relations website, with a replay accessible for 90 days post-event. R1 RCM focuses on improving patient experience and financial performance for healthcare organizations.

R1 RCM Inc. (NASDAQ: RCM) announced its financial results for Q4 and the full year 2022 on February 16, 2023. Q4 revenue reached $532.8 million, marking a 33.6% increase compared to Q4 2021. However, the company reported a GAAP net loss of $37.1 million, down from a net income of $36.0 million in the same quarter last year. For the full year, R1 generated $1,806.4 million in revenue, a 22.5% increase year-over-year, but also registered a net loss of $57.6 million. The company anticipates 2023 revenue between $2,280 million and $2,330 million and adjusted EBITDA of $595 million to $630 million.

R1 RCM (NASDAQ: RCM) announced its recognition as the market leader in Ambulatory Revenue Cycle Management Services for the third consecutive year by KLAS. R1 also secured top positions in Denials Management Services and Robotic Process Automation through its subsidiary Cloudmed. The recognition emphasizes R1’s effective technology solutions that help healthcare providers enhance financial performance amidst industry challenges like labor shortages and rising costs. The firm aims to alleviate administrative burdens, allowing providers to focus on patient care.